Xing Wu, MD, PhD, Zhexin Yu, MD, MS, Wen Su, MD, PhD, Daniel A

Slides:

Advertisements

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Advertisements

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels Michael H. Davidson, MD Journal of Clinical.

Wijtske Annema, PhD, Hendrik M

Modulation of High-Density Lipoproteins in a Population in Istanbul, Turkey, With Low Levels of High-Density Lipoproteins Robert W. Mahley, MD, PhD,

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients Chun-Chin Chang, MD, Yung-Tai.

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

An assessment by the Statin Liver Safety Task Force: 2014 update

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Rounding numbers The Journal of Thoracic and Cardiovascular Surgery

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men Gloria Lena Vega, PhD, Scott M. Grundy,

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Lipoprotein insulin resistance score and risk of incident diabetes during extended follow- up of 20 years: The Women's Health Study Paulo H.N. Harada,

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Predictors of first-year statin medication discontinuation: A cohort study Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis Robert Wolk, MD, PhD, DSc, Ehrin J.

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients Chun-Chin Chang, MD, Yung-Tai.

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Non–high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial James D. Otvos,

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

High frequency of type 2 diabetes and impaired glucose tolerance in Japanese subjects with the angiopoietin-like protein 8 R59W variant Jianhui Liu,

Evaluation of the Clinical Usefulness of Critical Patient Severity Classification System and Glasgow Coma Scale for Neurological Patients in Intensive.

Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia Chang-Min.

An assessment by the Statin Intolerance Panel: 2014 update

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Hye-Ryoung Kim, PhD, Hee-Seung Kim, PhD Asian Nursing Research

Optimal high-density lipoprotein cholesterol cutoff for predicting cardiovascular disease: Comparison of the Korean and US National Health and Nutrition.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

The Reply The American Journal of Medicine

Elevated High-Density Lipoprotein Cholesterol Is Associated with Hyponatremia in Hypertensive Patients Ariel Israel, MD, PhD, Ehud Grossman, MD The.

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT.

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk Terry.

Christopher S. Penet, Brian H. Annex, MD, Kelly T. Gregory, R

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Volume 67, Issue 4, Pages (April 2005)

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

Urbanization, mainly rurality, but not altitude is associated with dyslipidemia profiles Maria Lazo-Porras, Antonio Bernabe-Ortiz, Renato Quispe, German.

Novel missense variants in LCAT and APOB genes in an Italian kindred with familial lecithin:cholesterol acyltransferase deficiency and hypobetalipoproteinemia

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design Dirk J. Blom, MD, PhD, Zahi A. Fayad,

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

Presentation transcript:

Low levels of ApoA1 improve risk prediction of type 2 diabetes mellitus Xing Wu, MD, PhD, Zhexin Yu, MD, MS, Wen Su, MD, PhD, Daniel A. Isquith, BS, Moni B. Neradilek, MS, Ning Lu, MD, Fusheng Gu, MD, Hongwei Li, MD, PhD, Xue-Qiao Zhao, MD Journal of Clinical Lipidology Volume 11, Issue 2, Pages 362-368 (March 2017) DOI: 10.1016/j.jacl.2017.01.009 Copyright © 2017 National Lipid Association Terms and Conditions

Figure 1 Study population and selection. Journal of Clinical Lipidology 2017 11, 362-368DOI: (10.1016/j.jacl.2017.01.009) Copyright © 2017 National Lipid Association Terms and Conditions

Figure 2 Apo A1 vs HDL-C by new diabetes status. Pearson correlation = 0.69, P < .001. APO, apolipoprotein; HDL-C, high-density lipoprotein cholesterol. Journal of Clinical Lipidology 2017 11, 362-368DOI: (10.1016/j.jacl.2017.01.009) Copyright © 2017 National Lipid Association Terms and Conditions

Figure 3 ROC curves for multivariate models for new T2DM. Panel A: black line represents the FDRSM model with AUC = 0.87; red line for adding ApoA1 to the model with AUC = 0.89, gold line that is superimposed with the red line for adding HDL-C/ApoA1 ratio to the model with AUC = 0.89. Panel B: The recently published 4-variable Chinese model in blue with AUC = 0.85; AUC improved to 0.89 when adding ApoA1 to the model in green, to 0.87 when adding HDL-C in purple, and to 0.86 when adding HDL-C/ApoA1 ratio in gold. Apo, apolipoprotein; AUC, area under the curve; FDRSM, Framingham Diabetes Risk Scoring Model; HDL-C, high-density lipoprotein-cholesterol; ROC, receiver operating characteristics; T2DM, type 2 diabetes mellitus. Journal of Clinical Lipidology 2017 11, 362-368DOI: (10.1016/j.jacl.2017.01.009) Copyright © 2017 National Lipid Association Terms and Conditions